Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06419634
PHASE1

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Sponsor: Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Official title: Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

105

Start Date

2024-05-29

Completion Date

2030-09-16

Last Updated

2026-04-08

Healthy Volunteers

No

Interventions

DRUG

BMS-986497

Specified dose on specified days

DRUG

Azacitidine

Specified dose on specified days

DRUG

Venetoclax

Specified dose on specified days

Locations (16)

Yale-New Haven Hospital

New Haven, Connecticut, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

Local Institution - 0007

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Washington University School of Medicine, Siteman Cancer Center

St Louis, Missouri, United States

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

Columbia University Irving Medical Center

New York, New York, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Local Institution - 0009

Fairfax, Virginia, United States

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Local Institution - 0017

Marseille, Bouches-du-Rhône, France

Local Institution - 0018

Paris, France

Local Institution - 0022

Toulouse, France

Hospital Clínic de Barcelona

Barcelona, Catalunya [Cataluña], Spain

Hospital Universitario Virgen Del Rocio

Seville, Spain